HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER
Clinical trials for HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to fight advanced cancers that stopped responding to prior therapies
Disease control Recruiting nowThis study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…
Matched conditions: HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Aminex Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug cocktail aims to wipe out HER2-Low breast cancer before surgery
Disease control Recruiting nowThis phase II trial is testing whether a targeted drug called trastuzumab deruxtecan (Enhertu), given alone or with anastrozole (Arimidex), can eliminate HER2-low, hormone receptor positive breast cancer before surgery. The study will enroll 88 people with early-stage breast canc…
Matched conditions: HER2-LOW HORMONE RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC